Filing summary
Entity and period: The supplied filing is Onconova Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015, not a filing under the name Traws Pharma, Inc. Verify the issuer and period against the original filing.
Business context and financial results
Onconova was a clinical-stage biopharmaceutical company developing oncology drug candidates, with most resources focused on rigosertib. The company reported minimal revenue and continuing operating losses.
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $123,000 | $125,000 | $237,000 | $572,000 |
| R&D expense | $6.512 million | $12.904 million | $16.010 million | $27.152 million |
| G&A expense | $2.568 million | $3.985 million | $5.533 million | $8.917 million |
| Operating loss | $8.957 million | $16.764 million | $21.306 million | $35.497 million |
| Net loss | $8.975 million | $16.780 million | $21.342 million | $35.496 million |
| Net loss per share | $0.41 | $0.77 | $0.98 | $1.64 |
At June 30, 2015, cash and cash equivalents were $25.358 million, down from $43.582 million at December 31, 2014. Six-month operating cash use was $18.327 million; investing cash flow was zero and financing provided $104,000. Working capital was $17.5 million. Total liabilities were $23.162 million, including $13.682 million of current and non-current deferred revenue; the balance sheet presents no borrowings. Stockholders’ equity was $4.575 million, versus $23.622 million at year-end 2014. The filing does not present a gross-margin measure.
Material changes and notable items
- Six-month revenue fell $335,000, primarily because Baxter-related R&D revenue recognition had been completed in the first quarter of 2014. Q2 revenue was nearly unchanged year over year.
- Six-month operating expenses fell $14.526 million, with R&D down $11.142 million and G&A down $3.384 million. Management attributed reductions to lower trial, consulting, manufacturing, personnel, and pre-commercialization costs, as well as workforce reductions.
- Cash declined by $18.224 million during the first half. Management said cost reductions were expected to extend the $25.4 million June cash balance into the first quarter of 2016.
- The 2014 Phase 3 ONTIME trial of intravenous rigosertib in higher-risk MDS did not meet its primary endpoint. Onconova planned a new Phase 3 trial in a defined patient population, subject to additional financing.
- In January 2015, Baxter’s successor, Baxalta, elected not to pursue further development of oral rigosertib for lower-risk MDS. Onconova retained the right to continue development itself. Baxalta’s spin-off became effective July 1, 2015.
- LLS funding of $8 million remained recorded as deferred revenue because repayment may be required if the program results in regulatory approval; additional milestone and royalty obligations may also apply.
Outlook, risks, and contingencies
Management anticipated continued operating losses and stated that additional financing would be needed to execute planned development. It was exploring equity, debt, strategic, and other funding sources, but gave no assurance financing would be available on acceptable terms or at all. Without funding, the company could delay, scale back, or eliminate programs and potentially cease operations. Financing needs could also delay the planned rigosertib Phase 3 trial.
Management expected enrollment in the new rigosertib IV Phase 3 trial to begin in the second half of 2015, subject to funding and regulatory submissions. Enrollment in the Phase 2 rigosertib-plus-azacitidine study was expected to finish in the second half of 2015, with data anticipated later in the year. These are forward-looking expectations, not reported outcomes. The filing reported no pending material legal proceedings and no material changes to previously disclosed risk factors.
Facts investors should verify
- Confirm the issuer: the supplied filing identifies Onconova Therapeutics, Inc., whereas the request metadata names Traws Pharma, Inc.
- Check subsequent cash, financing, and runway disclosures against the stated expectation of funding into Q1 2016.
- Verify whether the planned Phase 3 trial received funding, regulatory clearance, and enrolled patients as anticipated.
- Review later clinical results for rigosertib and the status of Baxalta/Baxalta Incorporated and SymBio collaboration rights and obligations.
- Assess the potential dilution and availability of the at-the-market equity program; the filing reported only $110,000 net proceeds from sales in the first half of 2015.